Form D · Biotechnology
Unum Therapeutics Inc.
Cambridge, MA · CIK 0001622229
Offering snapshot reported Jul 21, 2020 · SEC filing
- Reported sold
- $104M Offering amount: $104M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 9, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 21, 2020 | Initial | $104,400,000 | No comparison | 22 | SEC filing |
| Jul 21, 2020 | Initial | $44,812,154 | No comparison | 2 | SEC filing |
| Jun 25, 2015 | Initial | $65,000,000 | No comparison | 13 | SEC filing |
| Oct 20, 2014 | Initial | $6,252,685 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-371481
Source: Form D, filed Jul 21, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ben Auspitz | Director |
| Bruce Booth | Director |
| Chris Cain | Director |
| Karen Ferrante | Director |
| John L. Green | Executive |
| Peter Harwin | Director |
| Arlene Morris | Director |
| Liam Ratcliffe | Director |
| Matthew Ros | Director |
| Jessica Sachs | Executive |
| Christiana Stamoulis | Executive |
| Charles Wilson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Cambridge Park Drive Suite 3100
Cambridge, MA, 02140
Cambridge, MA, 02140